Stryker To Pay $1.4M Over Bone Protein Marketing

Law360, New York (August 26, 2010, 12:27 PM EDT) -- Stryker Biotech LLC has agreed to pay $1.35 million to Massachusetts to settle claims that the company marketed its OP-1 bone protein for uses not approved by the U.S. Food and Drug Administration.

In a consent judgment lodged Wednesday in the Suffolk County Superior Court in Massachusetts, Stryker Biotech agreed to pay $875,000 to fund efforts to combat unlawful marketing in the health care industry, Massachusetts Attorney General Martha Coakley said in a statement Thursday.

The company, a subsidiary of Michigan-based medical technology giant Stryker Corp.,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.